Nothing Special   »   [go: up one dir, main page]

PL1833799T3 - 3-Fenylo-pirazolowe pochodne jako modulatory 5-HT2A receptora serotoniny użyteczne w leczeniu zaburzeń związanych z tym receptorem - Google Patents

3-Fenylo-pirazolowe pochodne jako modulatory 5-HT2A receptora serotoniny użyteczne w leczeniu zaburzeń związanych z tym receptorem

Info

Publication number
PL1833799T3
PL1833799T3 PL05849546T PL05849546T PL1833799T3 PL 1833799 T3 PL1833799 T3 PL 1833799T3 PL 05849546 T PL05849546 T PL 05849546T PL 05849546 T PL05849546 T PL 05849546T PL 1833799 T3 PL1833799 T3 PL 1833799T3
Authority
PL
Poland
Prior art keywords
modulators
phenyl
treatment
disorders related
serotonin receptor
Prior art date
Application number
PL05849546T
Other languages
English (en)
Inventor
Bradley Teegarden
Yifeng Xiong
Sonja Strah-Pleynet
Honnappa Jayakumar
Peter I Dosa
Konrad Feichtinger
Martin Casper
Juerg Lehmann
Robert M Jones
David J Unett
Jin Sun Karoline Choi
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of PL1833799T3 publication Critical patent/PL1833799T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL05849546T 2004-11-19 2005-11-17 3-Fenylo-pirazolowe pochodne jako modulatory 5-HT2A receptora serotoniny użyteczne w leczeniu zaburzeń związanych z tym receptorem PL1833799T3 (pl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US62977404P 2004-11-19 2004-11-19
US64763905P 2005-01-26 2005-01-26
US65838405P 2005-03-02 2005-03-02
US71338405P 2005-09-01 2005-09-01
US73316505P 2005-11-04 2005-11-04
EP05849546A EP1833799B1 (en) 2004-11-19 2005-11-17 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT-2a SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
PCT/US2005/041726 WO2006055734A2 (en) 2004-11-19 2005-11-17 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto

Publications (1)

Publication Number Publication Date
PL1833799T3 true PL1833799T3 (pl) 2009-02-27

Family

ID=36218810

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05849546T PL1833799T3 (pl) 2004-11-19 2005-11-17 3-Fenylo-pirazolowe pochodne jako modulatory 5-HT2A receptora serotoniny użyteczne w leczeniu zaburzeń związanych z tym receptorem

Country Status (37)

Country Link
US (6) US20070244086A1 (pl)
EP (2) EP1833799B1 (pl)
JP (1) JP5016494B2 (pl)
KR (2) KR20130027039A (pl)
CN (3) CN102977029B (pl)
AR (1) AR051675A1 (pl)
AT (1) ATE407927T1 (pl)
AU (1) AU2005307744C1 (pl)
BR (1) BRPI0518446A2 (pl)
CA (1) CA2588513C (pl)
CR (1) CR9098A (pl)
CY (1) CY1108508T1 (pl)
DE (1) DE602005009748D1 (pl)
DK (1) DK1833799T3 (pl)
EA (1) EA011935B1 (pl)
ES (1) ES2314750T3 (pl)
GT (1) GT200500336A (pl)
HK (1) HK1102818A1 (pl)
HN (1) HN2005032627A (pl)
HR (1) HRP20080592T3 (pl)
IL (1) IL182945A (pl)
MA (1) MA29081B1 (pl)
MX (1) MX2007005959A (pl)
MY (1) MY147684A (pl)
NI (1) NI200700127A (pl)
NO (1) NO340656B1 (pl)
NZ (1) NZ554817A (pl)
PE (1) PE20061130A1 (pl)
PL (1) PL1833799T3 (pl)
PT (1) PT1833799E (pl)
RS (1) RS50698B (pl)
SA (1) SA05260357B1 (pl)
SI (1) SI1833799T1 (pl)
SV (1) SV2008002307A (pl)
TN (1) TNSN07188A1 (pl)
TW (2) TWI377059B (pl)
WO (1) WO2006055734A2 (pl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101157272B1 (ko) 2003-07-22 2012-06-15 아레나 파마슈티칼스, 인크. 5?ht2a 세로토닌 수용체의 조절자로서 이와 관련된질환의 예방 및 치료에 유용한 디아릴 및 아릴헤테로아릴우레아 유도체
ATE548353T1 (de) 2004-03-23 2012-03-15 Arena Pharm Inc Verfahren zur herstellung von substituierte n- aryl-n'-ä3-(1h-pyrazol-5-yl)phenylü-harnstoffe and intermediate davon.
SA05260357B1 (ar) * 2004-11-19 2008-09-08 ارينا فارماسيتو تيكالز ، أنك مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به
WO2007136703A1 (en) 2006-05-18 2007-11-29 Arena Pharmaceuticals, Inc. Primary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
CN104761498B (zh) * 2006-05-18 2017-12-26 艾尼纳制药公司 5‑ht2a血清素受体的调节剂
US8481535B2 (en) * 2006-05-18 2013-07-09 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor
WO2008027483A1 (en) * 2006-08-31 2008-03-06 Arena Pharmaceuticals, Inc. Benzofuran derivatives as modulators of the 5-ht2a receptor
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物
WO2008054748A2 (en) * 2006-10-31 2008-05-08 Arena Pharmaceuticals, Inc. Indazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
ITMI20062230A1 (it) * 2006-11-22 2008-05-23 Acraf Composto 2-alchil-indazolico procedimento per preparalo e composizione farmaceutica che lo comprende
JP5393677B2 (ja) 2007-08-15 2014-01-22 アリーナ ファーマシューティカルズ, インコーポレイテッド 5−HT2Aセロトニン受容体に関連した障害の治療のための5−HT2Aセロトニン受容体のモジュレーターとしてのイミダゾ[1,2−a]ピリジン誘導体
PT2222300E (pt) 2007-12-13 2014-07-28 Vanda Pharmaceuticals Inc Método e composição para tratamento de uma condição mediada por recetores da serotonina
BRPI0820993A2 (pt) 2007-12-13 2017-05-09 Vanda Pharmaceuticals Inc método e composição para tratar uma condição mediada por alfa adrenoceptor
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
CN109438352A (zh) 2008-10-28 2019-03-08 艾尼纳制药公司 治疗5-ht2a5-羟色胺受体相关障碍的5-ht2a5-羟色胺受体调节剂组合物
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
US8980891B2 (en) 2009-12-18 2015-03-17 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
EP2731561B1 (en) 2011-07-14 2016-03-23 Cook Medical Technologies LLC A sling to be used in the treatment of obstructive sleep apnea
US10314736B2 (en) 2012-10-16 2019-06-11 Cook Medical Technologies Llc Method and apparatus for treating obstructive sleep apnea (OSA)
CA2919504A1 (en) 2013-08-01 2015-02-05 Christine BRONIKOWSKI Tissue adjustment implant
CN105392433B (zh) 2013-08-05 2019-02-19 库克医学技术有限责任公司 具有可释放管状构件的医疗装置及其使用方法
EP2898920B1 (en) 2014-01-24 2018-06-06 Cook Medical Technologies LLC Articulating balloon catheter
US9974563B2 (en) 2014-05-28 2018-05-22 Cook Medical Technologies Llc Medical devices having a releasable member and methods of using the same
WO2016022454A1 (en) 2014-08-04 2016-02-11 Darin Schaeffer Medical devices having a releasable tubular member and methods of using the same
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーAxovant Sciences Gmbh レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
WO2017011767A2 (en) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
US11357660B2 (en) 2017-06-29 2022-06-14 Cook Medical Technologies, LLC Implantable medical devices for tissue repositioning
WO2019060298A1 (en) 2017-09-19 2019-03-28 Neuroenhancement Lab, LLC METHOD AND APPARATUS FOR NEURO-ACTIVATION
WO2019099307A1 (en) * 2017-11-17 2019-05-23 Hepagene Therapeutics, Inc. Urea derivatives as inhibitors of ask1
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US11273283B2 (en) 2017-12-31 2022-03-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
CA3112564A1 (en) 2018-09-14 2020-03-19 Neuroenhancement Lab, LLC System and method of improving sleep
CA3206840A1 (en) * 2020-12-31 2022-07-07 Arena Pharmaceuticals, Inc. Methods of treatment
WO2023122135A1 (en) * 2021-12-22 2023-06-29 Kuleon Llc Serotonin receptor agonists and methods of making and using the same
WO2024122617A1 (ja) * 2022-12-08 2024-06-13 塩野義製薬株式会社 セロトニン受容体結合活性を有する含窒素複素環および炭素環誘導体

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) * 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
DE2926517A1 (de) * 1979-06-30 1981-01-15 Beiersdorf Ag Substituierte 3-aryl-pyrazole und 5-aryl-isoxazole und verfahren zu ihrer herstellung
DE2928485A1 (de) * 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
US4985352A (en) 1988-02-29 1991-01-15 The Trustees Of Columbia University In The City Of New York DNA encoding serotonin 1C (5HT1c) receptor, isolated 5HT1c receptor, mammalian cells expressing same and uses thereof
US5661024A (en) * 1989-10-31 1997-08-26 Synaptic Pharmaceutical Corporation DNA encoding a human serotonic (5-HT2) receptor and uses thereof
US5077409A (en) * 1990-05-04 1991-12-31 American Cyanamid Company Method of preparing bis-aryl amide and urea antagonists of platelet activating factor
US5128351A (en) * 1990-05-04 1992-07-07 American Cyanamid Company Bis-aryl amide and urea antagonists of platelet activating factor
FR2682379B1 (fr) * 1991-10-09 1994-02-11 Rhone Poulenc Agrochimie Nouveaux phenylpyrazoles fongicides.
FR2690440B1 (fr) * 1992-04-27 1995-05-19 Rhone Poulenc Agrochimie Arylpyrazoles fongicides.
EP0714389B1 (en) * 1993-08-20 1998-06-17 Smithkline Beecham Plc Amide and urea derivatives as 5ht1d receptor antagonists
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
FR2722369B1 (fr) 1994-07-13 1998-07-10 Rhone Poulenc Agrochimie Compositions fongicides a base de derives 3-phenyl-pyrazoles pour le traitement du materiel vegetal de multiplication, nouveaux derives 3-phenyl-pyrazoles et leurs applications fongicides
AU3577995A (en) 1994-10-04 1996-04-26 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
AU699727B2 (en) * 1995-02-02 1998-12-10 Smithkline Beecham Plc Indole derivatives as 5-HT receptor antagonist
WO1996025157A1 (en) * 1995-02-17 1996-08-22 Smithkline Beecham Corporation Il-8 receptor antagonists
AU6526896A (en) 1995-07-22 1997-02-18 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
US6054472A (en) * 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US6005008A (en) * 1996-02-16 1999-12-21 Smithkline Beecham Corporation IL-8 receptor antagonists
GB9607219D0 (en) * 1996-04-04 1996-06-12 Smithkline Beecham Plc Novel compounds
ATE226189T1 (de) * 1996-05-24 2002-11-15 Neurosearch As Saure gruppen enthaltende phenylderivate, ihre herstellung und ihre verwendung als chloridkanalblocker
AU2962297A (en) 1996-05-24 1998-01-05 Neurosearch A/S Phenyl derivatives useful as blockers of chloride channels
IL127667A0 (en) * 1996-06-27 1999-10-28 Smithkline Beecham Corp IL-8 receptor antagonists
WO1998024785A1 (en) * 1996-12-02 1998-06-11 Fujisawa Pharmaceutical Co., Ltd. Indole-urea derivatives with 5-ht antagonist properties
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
US6541209B1 (en) 1997-04-14 2003-04-01 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6696475B2 (en) * 1997-04-22 2004-02-24 Neurosearch A/S Substituted phenyl derivatives, their preparation and use
AU728520B2 (en) * 1997-04-22 2001-01-11 Neurosearch A/S Substituted phenyl derivatives, their preparation and use
AU8673198A (en) 1997-07-29 1999-02-22 Smithkline Beecham Corporation Il-8 receptor antagonists
KR20010031557A (ko) * 1997-10-31 2001-04-16 추후제출 치환 아닐리드
ES2154252T3 (es) 1997-12-22 2005-12-01 Bayer Pharmaceuticals Corp. Inhibicion de quinasa p38 utilizando difenil-ureas simetricas y asimetricas.
US7517880B2 (en) * 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
ES2153809T3 (es) 1997-12-22 2005-07-16 Bayer Pharmaceuticals Corporation Inhibicion de la cinasa raf por uso de difnil-ureas sustituidas simetrica y asimetricamente.
ES2156845T1 (es) 1998-04-14 2001-08-01 Arena Pharm Inc Receptores de serotonina humana no endogenos constitutivamente activados y moduladores de moleculas pequeñas para estos.
US6140509A (en) * 1998-06-26 2000-10-31 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
GB9816263D0 (en) * 1998-07-24 1998-09-23 Merck Sharp & Dohme Therapeutic agents
CN1263733C (zh) * 1998-10-22 2006-07-12 神经研究公司 取代苯基衍生物,它们的制备和用途
US6150393A (en) 1998-12-18 2000-11-21 Arena Pharmaceuticals, Inc. Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors
CZ20013435A3 (cs) 1999-03-26 2002-04-17 Euro-Celtique S. A. Aryly substituované pyrazoly, imidazoly, oxazoly, thiazoly a pyrroly a jejich pouľití
GB9909409D0 (en) 1999-04-24 1999-06-23 Zeneca Ltd Chemical compounds
WO2001021160A2 (en) 1999-09-23 2001-03-29 Axxima Pharmaceuticals Aktiengesellschaft Carboxymide and aniline derivatives as selective inhibitors of pathogens
US6531291B1 (en) * 1999-11-10 2003-03-11 The Trustees Of Columbia University In The City Of New York Antimicrobial activity of gemfibrozil and related compounds and derivatives and metabolites thereof
EP1108720A1 (en) 1999-12-08 2001-06-20 Basf Aktiengesellschaft Herbicidal 2-Pyrazolyl-6-Aryloxy-Pyri(mi)dines
FR2810979B1 (fr) * 2000-06-29 2002-08-23 Adir Nouveaux derives de diphenyluree, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2002039987A2 (en) 2000-11-14 2002-05-23 Neurosearch A/S Use of malaria parasite anion channel blockers for treating malaria
AR035521A1 (es) 2000-12-22 2004-06-02 Lundbeck & Co As H Derivados de 3-indolina y composicion farmaceutica que los comprende
US20020156068A1 (en) 2001-03-22 2002-10-24 Behan Dominic P. Anti-psychosis combination
KR100908176B1 (ko) * 2001-09-21 2009-07-16 브리스톨-마이어스스퀴브컴파니 인자 Xa 억제제로서의 락탐-함유 화합물 및 그의 유도체
EP1509505A2 (en) * 2002-01-23 2005-03-02 Arena Pharmaceuticals, Inc. SMALL MOLECULE MODULATORS OF THE 5−HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO
WO2004028450A2 (en) 2002-09-24 2004-04-08 Arena Pharmaceuticals, Inc. Process of making phenylpyrazoles useful as selective 5ht2a modulators and intermediates thereof
AU2003290638A1 (en) 2002-11-08 2004-06-03 Interdigital Technology Corporation Composite channel quality estimation techniques for wireless receivers
US20060229335A1 (en) * 2002-12-24 2006-10-12 Bradley Teegarden Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a
CA2515544A1 (en) 2003-02-11 2004-08-26 Kemia Inc. Compounds for the treatment of viral infection
JP2006521345A (ja) 2003-03-28 2006-09-21 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ニコチン性アセチルコリン受容体の正のアロステリック調節剤
GB0309781D0 (en) 2003-04-29 2003-06-04 Glaxo Group Ltd Compounds
KR101157272B1 (ko) * 2003-07-22 2012-06-15 아레나 파마슈티칼스, 인크. 5?ht2a 세로토닌 수용체의 조절자로서 이와 관련된질환의 예방 및 치료에 유용한 디아릴 및 아릴헤테로아릴우레아 유도체
US20050054691A1 (en) * 2003-08-29 2005-03-10 St. Jude Children's Research Hospital Carboxylesterase inhibitors
WO2005077345A1 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
ATE548353T1 (de) * 2004-03-23 2012-03-15 Arena Pharm Inc Verfahren zur herstellung von substituierte n- aryl-n'-ä3-(1h-pyrazol-5-yl)phenylü-harnstoffe and intermediate davon.
US20060014705A1 (en) * 2004-06-30 2006-01-19 Howitz Konrad T Compositions and methods for selectively activating human sirtuins
JP2008509982A (ja) 2004-08-16 2008-04-03 プロシディオン・リミテッド アリール尿素誘導体
US20060063754A1 (en) * 2004-09-21 2006-03-23 Edgar Dale M Methods of treating a sleep disorder
US7846915B2 (en) * 2004-10-20 2010-12-07 Resverlogix Corporation Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
US20090239841A1 (en) 2004-10-27 2009-09-24 Hutchison Alan J Diaryl Ureas as CB1 Antagonists
WO2006049734A2 (en) 2004-10-29 2006-05-11 Hypnion, Inc. Quetiapine analogs and methods of use thereof
SA05260357B1 (ar) 2004-11-19 2008-09-08 ارينا فارماسيتو تيكالز ، أنك مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به
AR051978A1 (es) 2004-12-01 2007-02-21 Divergence Inc Composiciones plaguicidas y metodos
GB0426313D0 (en) 2004-12-01 2005-01-05 Merck Sharp & Dohme Therapeutic agents
WO2006060762A2 (en) * 2004-12-03 2006-06-08 Arena Pharmaceuticals, Inc. Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
WO2006070394A1 (en) 2004-12-28 2006-07-06 Council Of Scientific And Industrial Research Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors
PL1858877T3 (pl) 2005-01-14 2014-08-29 Gilead Connecticut Inc 1,3 podstawione diarylem moczniki jako modulatory aktywności kinazy
EP1843762A1 (en) 2005-01-19 2007-10-17 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis or treatment of progressive multifocal leukoencephalopathy
AR052886A1 (es) 2005-01-26 2007-04-11 Arena Pharm Inc Procedimientos para preparar fenilpirazol ureas sustituidas y para la obtencion de sus intermediarios de sintesis
EP1846415B1 (en) 2005-01-27 2012-08-01 Janssen Pharmaceutica NV Heterocyclic tetracyclic tetrahydrofuran derivatives as 5ht2 inhibitors in the treatment of cns disorders
GT200600042A (es) 2005-02-10 2006-09-27 Aventis Pharma Inc Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a
WO2006089871A2 (en) 2005-02-23 2006-08-31 Neurosearch A/S Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias
GB0504828D0 (en) 2005-03-09 2005-04-13 Merck Sharp & Dohme Therapeutic agents
GB0505437D0 (en) 2005-03-17 2005-04-20 Merck Sharp & Dohme Therapeutic agents
GB0505725D0 (en) 2005-03-19 2005-04-27 Merck Sharp & Dohme Therapeutic agents
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
CA2606471C (en) 2005-04-26 2014-02-11 Hypnion, Inc. Benzisoxazole piperidine compounds and methods of use thereof
EP1734039A1 (en) 2005-06-13 2006-12-20 Esbatech AG Aryl urea compounds as BETA-secretase inhibitors
US8569352B2 (en) 2005-06-27 2013-10-29 Exelixis Patent Company Llc Imidazole based LXR modulators
US8093401B2 (en) * 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
TWI329641B (en) 2005-08-31 2010-09-01 Otsuka Pharma Co Ltd (benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same
JP2009533442A (ja) 2006-04-10 2009-09-17 アリーナ ファーマシューティカルズ, インコーポレイテッド 5−ht2aセロトニン受容体関連障害の治療のために有用な5−ht2aセロトニン受容体のモジュレータとしての3−ピリジニル−ピラゾール誘導体
GB0608655D0 (en) 2006-05-03 2006-06-14 Merck Sharp & Dohme Therapeutic Treatment
CN104761498B (zh) 2006-05-18 2017-12-26 艾尼纳制药公司 5‑ht2a血清素受体的调节剂
US8481535B2 (en) 2006-05-18 2013-07-09 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor
WO2007136703A1 (en) 2006-05-18 2007-11-29 Arena Pharmaceuticals, Inc. Primary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
EP2051978A2 (en) 2006-05-18 2009-04-29 Arena Pharmaceuticals, Inc. Acetamide derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
WO2008027483A1 (en) 2006-08-31 2008-03-06 Arena Pharmaceuticals, Inc. Benzofuran derivatives as modulators of the 5-ht2a receptor
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物
WO2008054748A2 (en) 2006-10-31 2008-05-08 Arena Pharmaceuticals, Inc. Indazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
JP5393677B2 (ja) 2007-08-15 2014-01-22 アリーナ ファーマシューティカルズ, インコーポレイテッド 5−HT2Aセロトニン受容体に関連した障害の治療のための5−HT2Aセロトニン受容体のモジュレーターとしてのイミダゾ[1,2−a]ピリジン誘導体
JP2009196349A (ja) * 2008-01-25 2009-09-03 Canon Finetech Inc バーコード印刷装置およびバーコード印刷方法
US8980891B2 (en) 2009-12-18 2015-03-17 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto

Also Published As

Publication number Publication date
KR20070086357A (ko) 2007-08-27
CY1108508T1 (el) 2014-04-09
AU2005307744C1 (en) 2011-11-24
US20070244086A1 (en) 2007-10-18
HN2005032627A (es) 2010-08-19
AU2005307744B2 (en) 2011-06-09
CN102977029A (zh) 2013-03-20
RS50698B (sr) 2010-06-30
US20130237540A1 (en) 2013-09-12
HRP20080592T3 (en) 2009-01-31
SA05260357B1 (ar) 2008-09-08
NI200700127A (es) 2008-06-05
ES2314750T3 (es) 2009-03-16
BRPI0518446A2 (pt) 2008-11-18
NZ554817A (en) 2011-01-28
EP1833799B1 (en) 2008-09-10
AU2005307744A1 (en) 2006-05-26
KR101275380B1 (ko) 2013-06-25
SI1833799T1 (sl) 2009-02-28
GT200500336A (es) 2006-06-22
CA2588513C (en) 2013-08-06
TWI409062B (zh) 2013-09-21
NO20072986L (no) 2007-08-20
CN103012378A (zh) 2013-04-03
MX2007005959A (es) 2007-07-04
AU2005307744B8 (en) 2011-08-04
MY147684A (en) 2012-12-31
US10781180B2 (en) 2020-09-22
IL182945A (en) 2012-06-28
PE20061130A1 (es) 2007-01-05
US20160304463A1 (en) 2016-10-20
CN101084195A (zh) 2007-12-05
EP1833799A2 (en) 2007-09-19
KR20130027039A (ko) 2013-03-14
MA29081B1 (fr) 2007-12-03
US7884101B2 (en) 2011-02-08
CR9098A (es) 2008-02-21
US8785441B2 (en) 2014-07-22
DK1833799T3 (da) 2009-01-19
TNSN07188A1 (en) 2008-11-21
ATE407927T1 (de) 2008-09-15
EA011935B1 (ru) 2009-06-30
EP1978019A1 (en) 2008-10-08
IL182945A0 (en) 2007-09-20
DE602005009748D1 (de) 2008-10-23
HK1102818A1 (en) 2007-12-07
NO340656B1 (no) 2017-05-22
US20190263757A1 (en) 2019-08-29
WO2006055734A2 (en) 2006-05-26
US20110105456A1 (en) 2011-05-05
CN102977029B (zh) 2017-12-19
WO2006055734A3 (en) 2006-08-17
TW200618798A (en) 2006-06-16
JP2008520695A (ja) 2008-06-19
JP5016494B2 (ja) 2012-09-05
EA200701101A1 (ru) 2007-12-28
TWI377059B (en) 2012-11-21
CA2588513A1 (en) 2006-05-26
US20070207994A1 (en) 2007-09-06
AR051675A1 (es) 2007-01-31
PT1833799E (pt) 2008-12-12
SV2008002307A (es) 2008-02-08
CN101084195B (zh) 2013-01-02
TW201231052A (en) 2012-08-01

Similar Documents

Publication Publication Date Title
PT1833799E (pt) Derivados de 3-fenil-pirazole como moduladores do receptor 5-ht2a de serotonina úteis no tratamento de desordens que lhe estão relacionadas
HK1121448A1 (en) Primary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto 5-th2a
ZA200802608B (en) Pharmaceutical compositions of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto
IL179508A0 (en) 2-substituted-4- heteroaryl-pyrimidines useful for the treatment of proliferative disorders
ZA200609234B (en) Substituted azeplne derivatives as serotonin receptor modulators
IL182685A0 (en) Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
EP1853539A4 (en) HONOKIOL DERIVATIVES TO TREAT PROLIFERATIVE DISEASES
IL185016A0 (en) Compounds for the treatment of proliferative disorders
IL178648A0 (en) Substituted morpholine compounds for the treatment of central nervous system disorders
ZA200801888B (en) Derivatives of 4-piperazin-1-1-YL-4-benzo [B] thiophene suitable for the treatment of CNS disorders
IL182365A0 (en) 5-sulfonyl-1-piperidinyl substituted indole derivatives as 5-ht6 receptor antagonists for the treatment of cns disorders
PL2364142T3 (pl) Kompozycje modulatora receptora 5-HT<sub>2A</sub> serotoniny przydatne do leczenia związanych z nim zaburzeń
IL179609A0 (en) Imidazole variants as modulators of gaba receptor for the treatment of gi disorders
PT2418201E (pt) Formas polimorfas de (2s)-(4e)-n-metil-5-[3-(5- isopropoxipiridin)il]-4-penten-2-amina para o tratamento de distúrbios do sistema nervoso central
HK1121453A1 (en) Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor 5-ht2a
ZA200700684B (en) Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators
ZA200703389B (en) Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
SI2024368T1 (sl) Derivati 6,7,8,9-tetrahidro-5h-pirimido(4,5-d)azepin-4-il)-amina kot modulatorji trpv 1 za zdravljenje boleäśine
IL188856A0 (en) Novel piperidine derivatives as chemokine receptor modulators useful for the treatment of respiratory diseases
ZA200703060B (en) Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to odulation of the dopamine d3 receptor
PT1737820E (pt) Processo de hidrogenação assimétrica útil para a preparação de derivados de cicloalcanoindole
ZA200703201B (en) Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
ZA200703885B (en) 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
ZA200808813B (en) Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor
GB0408297D0 (en) Indole derivatives for the treatment of diseases